Chemed Corporation
CHE
$485.37
+1.01%
Chemed Corporation operates through two distinct segments: VITAS, which provides hospice and palliative care services to terminally ill patients, and Roto-Rooter, which offers plumbing, drain cleaning, and water restoration services. As a diversified holding company, Chemed holds leading market positions in both hospice care and residential/commercial plumbing services, benefiting from demographic tailwinds in end-of-life care and recurring demand for essential home services. The current investor narrative centers on the company's robust cash generation and shareholder return program, highlighted by a recent $300 million stock buyback authorization and consistent dividend growth, while also grappling with near-term revenue deceleration in its hospice segment amid regulatory and reimbursement headwinds.…
CHE
Chemed Corporation
$485.37
Related headlines
Investment Opinion: Should I buy CHE Today?
Rating: Hold. Chemed is a high-quality, defensive business with strong cash flows and a low debt burden, but its lack of revenue growth and margin compression limit near-term upside. The single analyst's EPS estimate of $28.85 implies a forward P/E of 18.2x, which is reasonable but not compelling given the stagnant top line.
Supporting evidence: The trailing P/E of 23.2x is below its five-year average of ~28x, suggesting relative value. However, revenue growth is flat (-0.1% YoY), and gross margins have declined 440 bps year-over-year. Free cash flow of $325.5 million TTM is robust, and the $300 million buyback authorization provides downside support. The ROE of 27.1% is excellent, but partly driven by share repurchases rather than organic growth.
Risks & Conditions: The biggest risks are continued margin compression and failure to reignite revenue growth. This Hold rating would upgrade to Buy if gross margins stabilize above 34% or if revenue growth accelerates above 3% YoY. It would downgrade to Sell if margins fall below 30% or if the forward P/E expands above 22x without earnings growth. Overall, Chemed appears fairly valued relative to its history and peers, given its defensive qualities but lack of growth.
Sign up to view all
CHE 12-Month Price Forecast
Chemed's outlook is balanced: the stock offers downside protection from its low valuation and strong cash flows, but upside catalysts are lacking given the flat revenue and margin pressure. The base case of a range-bound stock is most likely, with a 50% probability. A bull case requires margin stabilization and modest growth, while a bear case hinges on further margin erosion. The neutral stance reflects the absence of a clear catalyst to break the current trend. Upgrades would require evidence of margin improvement or revenue acceleration; downgrades would follow continued deterioration.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Chemed Corporation's 12-month outlook, with a consensus price target around $630.98 and implied upside of +30.0% versus the current price.
Average Target
$630.98
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$388 - $631
Analyst target range
Only one analyst covers Chemed, which is insufficient for a consensus view. The single analyst estimates EPS of $28.85 for the current fiscal year, with a range of $28.72 to $28.96, and revenue of $3.01 billion. Given the limited coverage, there is no formal Buy/Hold/Sell distribution or average target price. The lack of analyst coverage implies that Chemed is a smaller-cap or less-followed stock, which can lead to higher volatility and less efficient price discovery. The limited coverage is surprising given the company's $6.2 billion market cap, but it may reflect the company's complex structure as a holding company. Institutional ratings show a mix of opinions: Oppenheimer rates it Outperform, RBC Capital downgraded to Sector Perform in February 2026, and Jefferies downgraded to Hold in January 2026. This mixed sentiment suggests uncertainty about the company's near-term prospects. Without a consensus target, investors must rely on fundamental analysis and valuation to gauge potential upside. The wide range of ratings (from Outperform to Hold) indicates divergent views, and the recent downgrades may reflect concerns about revenue growth and margin pressure.
Drowning in data?
Find the real signal!
Bulls vs Bears: CHE Investment Factors
Chemed presents a mixed picture: strong cash flows, low debt, and a defensive business model are offset by stagnant revenue and margin compression. The bull case rests on the company's ability to stabilize margins and deploy its $300 million buyback to support EPS growth, while the bear case highlights the lack of top-line growth and analyst downgrades. The single most important tension is whether Chemed can reverse its margin decline and return to revenue growth; if it does, the stock could re-rate higher given its undemanding forward P/E, but if margins continue to erode, earnings could disappoint. Currently, the evidence slightly favors the bear case due to the absence of a clear growth catalyst.
Bullish
- Strong Free Cash Flow Generation: Chemed generated $325.5 million in trailing twelve-month free cash flow, providing ample liquidity for its $300 million buyback authorization and consistent dividend growth. This cash generation supports shareholder returns even amid revenue stagnation.
- Low Debt and High ROE: With a debt-to-equity ratio of just 0.16 and ROE of 27.1%, Chemed maintains a fortress balance sheet and efficient capital allocation. The low leverage provides financial flexibility and resilience in downturns.
- Attractive Forward Valuation: The forward P/E of 18.2x is near the lower end of its five-year historical range (19x-38x) and only slightly above the industry forward average of ~16x. This suggests limited downside risk if earnings materialize as expected.
- Defensive Business Mix: With a beta of 0.52, Chemed is significantly less volatile than the market. Its hospice and plumbing services are essential and recurring, providing stable demand regardless of economic conditions.
Bearish
- Flat Revenue Growth: Revenue in Q4 2025 was $639.3 million, essentially unchanged year-over-year (-0.1%). Over the trailing four quarters, revenue has fluctuated between $618.8 million and $646.9 million, indicating no organic growth.
- Margin Compression: Gross margin declined from 36.6% in Q4 2024 to 32.2% in Q4 2025, and operating margin fell from 17.8% to 15.7%. Rising labor costs in hospice care are pressuring profitability.
- Limited Analyst Coverage: Only one analyst covers Chemed, providing no consensus target or clear buy/sell signal. This lack of coverage can lead to inefficient price discovery and higher information risk for investors.
- Recent Downgrades by Analysts: RBC Capital downgraded to Sector Perform in February 2026 and Jefferies downgraded to Hold in January 2026, reflecting skepticism about near-term growth prospects amid regulatory headwinds.
CHE Technical Analysis
Chemed is in a strong recovery uptrend, with the stock up 3.9% over the past year and currently trading at $489.66, which is 99.5% of its 52-week high of $492.30. The price sits just 0.5% below the 52-week high, indicating bullish momentum and positioning near the top of its 52-week range of $365.21 to $492.30. This near-high positioning suggests the stock is enjoying strong upward momentum, though it also raises the risk of short-term overextension. The stock has rallied 17.4% in the past month and 28.7% over the past three months, significantly outpacing the S&P 500's 1-month decline of 1.25% and 3-month gain of 13.56%. This short-term acceleration is consistent with the longer-term uptrend, showing no divergence. The relative strength versus the S&P 500 is strongly positive at +18.6% over one month and +15.1% over three months, confirming broad-based buying interest. The 52-week low of $365.21 provides a key support level, while the 52-week high of $492.30 is the immediate resistance. A breakout above $492.30 could signal a continuation of the uptrend toward new highs, while a breakdown below $365.21 would indicate a bearish reversal. With a beta of 0.52, Chemed is significantly less volatile than the broader market, meaning it tends to experience smaller price swings, which may appeal to risk-averse investors but also implies lower upside participation during market rallies.
Beta
0.52
0.52x market volatility
Max Drawdown
-35.4%
Largest decline past year
52-Week Range
$365-$492
Price range past year
Annual Return
+5.4%
Cumulative gain past year
| Period | CHE Return | S&P 500 |
|---|---|---|
| 1m | +9.9% | +1.4% |
| 3m | +22.8% | +10.6% |
| 6m | +8.1% | +8.4% |
| 1y | +5.4% | +20.5% |
| ytd | +14.5% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CHE Fundamental Analysis
Chemed's revenue trajectory has been relatively flat, with the most recent quarter (Q4 2025) reporting $639.3 million, essentially unchanged year-over-year (0.1% decline). Over the trailing four quarters, revenue has ranged from $618.8 million to $646.9 million, showing modest fluctuation but no clear growth trend. The VITAS segment generated $429.9 million in revenue, while Roto-Rooter contributed $231.6 million, indicating hospice care is the primary growth driver, though it faces reimbursement headwinds. The lack of top-line growth is a concern for the investment case, as it suggests limited organic expansion. Chemed is profitable, with net income of $76.8 million in Q4 2025 and a net margin of 12.0%. Gross margin has been volatile, declining from 36.6% in Q4 2024 to 32.2% in Q4 2025, indicating margin compression likely due to rising labor costs in hospice care. Operating margin also fell from 17.8% to 15.7% over the same period. While still healthy, the margin contraction is a watchpoint, as it could pressure earnings if revenue growth remains stagnant. Chemed maintains a strong balance sheet with a debt-to-equity ratio of just 0.16, indicating minimal leverage. Free cash flow (FCF) was $117.2 million in Q4 2025, and trailing twelve-month FCF totaled $325.5 million, providing ample liquidity for buybacks and dividends. The company generated $133.5 million in operating cash flow in Q4, easily covering capital expenditures of $16.3 million. Return on equity (ROE) stands at 27.1%, reflecting efficient capital allocation, though this is partly boosted by share repurchases. The current ratio of 1.05 suggests adequate short-term liquidity, though it is relatively low for a services company.
Quarterly Revenue
$639337000.0B
2025-12
Revenue YoY Growth
-0.10%
YoY Comparison
Gross Margin
32.22%
Latest Quarter
Free Cash Flow
$325477000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CHE Overvalued?
Since Chemed has positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 23.2x, while the forward P/E is 18.2x, implying the market expects earnings growth in the coming year. The gap between trailing and forward P/E suggests analysts anticipate earnings improvement, which is consistent with the company's margin recovery efforts. Compared to the industry average (Medical - Care Facilities), Chemed's trailing P/E of 23.2x is at a premium to the sector median of approximately 18x (based on industry data), representing a 29% premium. This premium may be justified by Chemed's strong free cash flow generation, low debt, and dominant market positions in hospice and plumbing services, which provide defensive characteristics. However, the premium is narrower on a forward basis (18.2x vs. industry forward ~16x), suggesting the market is pricing in some earnings normalization. Historically, Chemed's trailing P/E has ranged from roughly 19x to 38x over the past five years. The current 23.2x is near the lower end of that range, indicating the stock is relatively cheap compared to its own history. This suggests that the market may be discounting near-term headwinds, and if growth reaccelerates, multiple expansion could provide upside. The P/B ratio of 6.3x is also below its five-year average of ~8x, further supporting a value-oriented assessment.
PE
23.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 20x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Chemed's primary financial risk is margin compression, with gross margin falling from 36.6% to 32.2% year-over-year in Q4 2025. This is driven by rising labor costs in the VITAS hospice segment, which accounts for 67% of revenue. If margins continue to decline, net income could fall even if revenue stabilizes. Additionally, the company's current ratio of 1.05 is relatively low for a services company, indicating limited short-term liquidity buffer. However, strong free cash flow ($325.5 million TTM) mitigates this risk. The debt-to-equity ratio of 0.16 is very low, so financial leverage is not a concern.
Market & Competitive Risks: Chemed trades at a trailing P/E of 23.2x, a 29% premium to the industry median of ~18x. This premium could compress if growth fails to materialize, especially given the flat revenue trend. The stock's beta of 0.52 suggests low market correlation, but it is still exposed to sector-specific risks such as Medicare reimbursement changes for hospice care. Recent analyst downgrades (RBC to Sector Perform, Jefferies to Hold) highlight growing skepticism. The lack of analyst coverage (only one analyst) also increases information asymmetry and potential volatility.
Worst-Case Scenario: In a severe scenario, continued margin erosion and revenue stagnation could lead to earnings disappointment, triggering further downgrades and multiple compression. The 52-week low of $365.21 represents a 25.4% decline from the current price of $489.66. If the stock revisits that level, an investor could lose approximately 25% from today's price. Historical max drawdown of -35.88% suggests even deeper losses are possible in a prolonged downturn.
FAQ
The key risks are: 1) Margin compression – gross margin fell from 36.6% to 32.2% YoY due to rising labor costs, which could further pressure earnings. 2) Revenue stagnation – revenue growth was -0.1% YoY, and there is no clear catalyst for acceleration. 3) Regulatory risk – changes in Medicare reimbursement for hospice care could negatively impact VITAS, which generates 67% of revenue. 4) Limited analyst coverage – only one analyst covers the stock, leading to potential information asymmetry and volatility. The most severe risk is a combination of margin erosion and revenue decline, which could push the stock toward its 52-week low of $365.21, a 25% downside from current levels.
The 12-month forecast is mixed. The base case (50% probability) sees the stock trading in a range of $460-$510, supported by buybacks and dividends but limited by flat revenue. The bull case (25% probability) targets $530-$570 if margins stabilize and growth returns. The bear case (25% probability) sees the stock falling to $370-$420 if margins deteriorate further. The single analyst estimates EPS of $28.85 for the current fiscal year, which at the current price implies a forward P/E of 18.2x. The most likely scenario is the base case, given the lack of near-term catalysts.
Chemed appears fairly valued to slightly undervalued based on its own history, but slightly overvalued relative to the industry. The trailing P/E of 23.2x is below its five-year average of ~28x, suggesting it is cheap relative to its own past. However, it trades at a 29% premium to the industry median trailing P/E of ~18x. On a forward basis, the P/E of 18.2x is closer to the industry forward average of ~16x, indicating the premium is narrowing. The P/B ratio of 6.3x is also below its five-year average of ~8x. Overall, the market is pricing in near-term headwinds, and if earnings stabilize, the stock could be undervalued.
Chemed is a reasonable buy for conservative investors seeking defensive exposure and income, but not for those seeking growth. The stock offers a forward P/E of 18.2x, which is near the low end of its historical range, and a dividend yield of 0.51% with a low payout ratio of 11.9%, suggesting room for increases. The $300 million buyback authorization provides downside support. However, the lack of revenue growth (-0.1% YoY) and margin compression (gross margin down 440 bps) limit upside. The single analyst's EPS estimate of $28.85 implies modest earnings growth, but this is uncertain. For long-term, risk-averse investors, CHE is a hold; for growth-oriented investors, it is less attractive.
Chemed is better suited for long-term investment due to its defensive business model, low beta of 0.52, and strong cash flows. Short-term trading is less attractive given the stock's low volatility and lack of near-term catalysts. The dividend yield of 0.51% and consistent buybacks provide a total return profile that compounds over time. A suggested minimum holding period is 3-5 years to allow for margin recovery and potential multiple expansion. For short-term traders, the stock's tight range and low beta offer limited opportunities, though the recent uptrend near the 52-week high could provide a breakout trade if volume picks up.
